Lead Ferroptosis Inhibitor

About Kalaris Therapeutics

Kalaris Therapeutics' mission is to pioneer a new class of neuroprotective medicines by selectively inhibiting ferroptosis, a key driver of cell death in central nervous system disorders. The company has advanced its scientific platform to the clinical stage, establishing itself as a leader in translating ferroptosis biology into therapeutic candidates. Its strategy involves validating its lead asset in targeted neurological indications to de-risk the platform, which could then be expanded across a broad spectrum of neurodegenerative and neuropsychiatric diseases. Success hinges on demonstrating clinical proof-of-concept in its ongoing trials.

About Kalaris Therapeutics

Kalaris Therapeutics' mission is to pioneer a new class of neuroprotective medicines by selectively inhibiting ferroptosis, a key driver of cell death in central nervous system disorders. The company has advanced its scientific platform to the clinical stage, establishing itself as a leader in translating ferroptosis biology into therapeutic candidates. Its strategy involves validating its lead asset in targeted neurological indications to de-risk the platform, which could then be expanded across a broad spectrum of neurodegenerative and neuropsychiatric diseases. Success hinges on demonstrating clinical proof-of-concept in its ongoing trials.

Therapeutic Areas